Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026

Annexon, Inc.

2025-Q3 EPS reported -$1.08

Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.
R&D expenses $49.7M, up from $30.1M, driven by Phase 3 ARCHER II trial and global GBS regulatory filings.
Cash and equivalents $188.7M as of Sep 30, 2025; operations funded into late Q1 2027 through key milestones.
Tanruprubart (ANX005) GBS MAA submission on track for Jan 2026; FDA discussions on BLA generalizability package ongoing.
Vonaprument (ANX007) Phase 3 ARCHER II trial enrolled 659 GA patients; topline data expected second half 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.